GUJTHEMBSEGujarat Themis Biosyn Ltd· Pharmaceuticals & BiotechnologyHighNegative
Announced Tue, 23 Sept, 2025 · 13:26 IST

Please refer to the attachment.

GUJTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.7%Reaction day
₹414.80
prior close
₹409.85
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.3%-1.4% vs market
Pharmaceuticals peers, median of 154sector-0.4%-1.3% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.0
10m
+0.1
15m
+0.1
30m
+0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.7-0.3-1.4-0.4-1.3
Next day
-1.3-0.6-0.6-0.7-0.6
2d
-1.2-1.7+0.5-1.4+0.3
3d
-4.1-3.8-0.3-3.3-0.7
4d
-4.4-4.6+0.2-3.4-1.0
5d
-5.0-5.0-0.0-3.3-1.7
1w
+2.0-2.4+4.3-2.3+4.2
15d
+3.3-3.0+6.2-4.0+7.2
1m
+8.9-1.4+10.3-2.9+11.8
2m
-3.4-4.9+1.5-6.3+2.9
3m
-1.6-5.9+4.3-6.7+5.1
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

BSE's Surveillance Department asked Gujarat Themis Biosyn to explain a sudden rise in trading volume of its shares on September 23, 2025. The company replied that it has made all required disclosures under SEBI's listing rules on time. It confirmed there is no pending material information, announcement, or event that could explain the unusual price or volume movement. The response was signed by the Company Secretary & Compliance Officer, Vineet Gawankar.

Likely market impact

This is a routine exchange query rather than a regulatory action — the company's denial of any hidden information is mildly reassuring for shareholders, though the unusual volume itself signals speculative interest worth monitoring. No immediate impact on fundamentals is indicated.